×
About 2,143 results

ALLMedicine™ Hypomagnesemia Center

Research & Reviews  619 results

Safety Assessment on Serious Adverse Events of Targeted Therapeutic Agents Prescribed f...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368240
International Journal of Environmental Research and Publi... Choi YJ, Choi CY et. al.

Aug 13th, 2022 - Despite substantially elevated risk of serious adverse events (SAEs) from targeted therapy in combination with chemotherapy, comprehensive pharmacovigilance research is limited. This study aims to systematically assess SAE risks of commonly prescr...

A Comparison of Panitumumab and Cetuximab in the Treatment of KRAS Wild-type Metastatic...
https://doi.org/10.1080/08923973.2022.2112222
Immunopharmacology and Immunotoxicology; Liu T, Jiang S et. al.

Aug 12th, 2022 - Cetuximab and panitumumab are common antibodies against epidermal growth factor receptor (EGFR) that can be used in combination with chemotherapy for the treatment of metastatic colorectal cancer (mCRC). Although these two drugs are considered to ...

Electrolytes disturbances in cancer patients.
https://doi.org/10.1097/MNH.0000000000000819
Current Opinion in Nephrology and Hypertension; Turcotte A, Achi S et. al.

Jul 28th, 2022 - Hypernatremia, hyperphosphatemia, hypocalcaemia, hyperkalaemia and hypermagnesemia are electrolytes disturbances that can arise in cancer patients in relation to unique causes that are related to the cancer itself or its treatment and can lead to ...

The genetic spectrum of Gitelman(-like) syndromes.
https://doi.org/10.1097/MNH.0000000000000818
Current Opinion in Nephrology and Hypertension; Schlingmann KP, de Baaij JHF

Jul 28th, 2022 - Gitelman syndrome is a recessive salt-wasting disorder characterized by hypomagnesemia, hypokalemia, metabolic alkalosis and hypocalciuria. The majority of patients are explained by mutations and deletions in the SLC12A3 gene, encoding the Na+-Cl-...

A case of Gitelman syndrome with membranous nephropathy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327143
BMC Nephrology; Guo X, Yu S et. al.

Jul 27th, 2022 - Gitelman syndrome (GS) is a rare autosomal recessive inherited salt-losing tubulopathy (SLT). Here, we report, for the first time, a case of GS overlapping nephrotic syndrome (NS) related to PLA2R-associated membranous nephropathy (MN). We describ...

see more →

Drugs  115 results see all →

Clinicaltrials.gov  47 results

Sarcopenia and Related Factors in Coronavirus Disease 2019 (COVID-19) Following Intensive Care
https://clinicaltrials.gov/ct2/show/NCT05474157

Jul 26th, 2022 - Patients with acute respiratory distress syndrome (ARDS) could develop muscle weakness associated with impairment of physical function defined as intensive care unit acquired weakness. Significant muscle loss occurs in the first week of the Intens...

Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplatin Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT04310826

Jun 24th, 2022 - PRIMARY OBJECTIVE: I. Evaluate intervention feasibility. SECONDARY OBJECTIVE: I. Evaluate occurrence of hypomagnesemia and the need for a pharmacy regimen including oral and intravenous magnesium dosage. EXPLORATORY OBJECTIVE: I. Explore changes i...

Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate
https://clinicaltrials.gov/ct2/show/NCT03812380

Jun 1st, 2022 - In a single-dose bioavailability study, the investigators showed previously that provision of calcium and magnesium in a soluble form as EffCaMgCit improved intestinal absorption of calcium and magnesium and suppressed parathyroid function during ...

Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
https://clinicaltrials.gov/ct2/show/NCT04166877

May 18th, 2022 - This is a single center, double blind, randomized controlled study to demonstrate the effectiveness of continuous, intravenous administration of magnesium sulfate as compared to placebo in decreasing pain in critically injured patients. Study Hypo...

Hypomagnesemia and Its Association With Calcineurin Inhibitors Use in Renal Transplant Recipients
https://clinicaltrials.gov/ct2/show/NCT05352880

Apr 29th, 2022 - Magnesium (Mg) is the fourth cation in the body and the second most prevalent intracellular cation. Intracellular magnesium concentrations range from 5 to 20 mmol/L; 1-5% of it is ionized, the remainder is bound to proteins. Extracellular Mg repre...

see more →

News  76 results

SL-172154 Shows Favorable Tolerability in Platinum-Resistant Ovarian Cancer
https://www.onclive.com/view/sl-172154-shows-favorable-tolerability-in-platinum-resistant-ovarian-cancer

Nov 17th, 2021 - The investigative agent SL-172154 (SIRPα-Fc-CD40L) was found to be well tolerated, with no dose-limiting toxicities (DLTs) observed, in patients with platinum-resistant ovarian cancer, according to findings from a phase 1 dose-escalation trial pre...

Novel and Alternative Strategies for Management of Panitumumab-Induced Hypomagnesemia
https://www.mdedge.com/fedprac/avaho/article/246950/oncology/novel-and-alternative-strategies-management-panitumumab
Katie Rogers, PharmD candidate (rogers.a.katie@utexas.edu), Sierra Vig, PharmD, BCOP, BCPS et. al.

Oct 1st, 2021 - Background Panitumumab is an epidermal growth factor receptor (EGFR) inhibiting monoclonal antibody approved for the treatment of RAS wild-type metastatic colorectal cancer (mCRC), which has an incidence of hypomagnesemia of approximately 35%. Gra.

Thoracic Leaders Examine Novel Treatment Options in Mesothelioma
https://www.onclive.com/view/thoracic-leaders-examine-novel-treatment-options-in-mesothelioma

Jun 23rd, 2021 - In a special OncLive video program, The Board, Joshua M. Bauml, MD, assistant professor of medicine, Perelman School of Medicine, University of Pennsylvania, led a discussion regarding key abstracts that were presented during the 2020 ASCO Virtual...

Cetuximab Safety Profile in Head and Neck Cancer
https://www.onclive.com/view/cetuximab-safety-profile-in-head-and-neck-cancer

Apr 2nd, 2021 - For High-Definition, Click Toxicities associated with cetuximab tend to be more tolerable than those observed with cytotoxic chemotherapy. The most concerning side effect, notes Robert Ferris, MD, is an anaphylactic infusion reaction, attributed...

BCL-2 Inhibitor Venetoclax Demonstrates Activity in Pretreated AML
https://www.onclive.com/view/bcl-2-inhibitor-venetoclax-demonstrates-activity-in-pretreated-aml

Dec 20th, 2020 - Marina Konopleva, MD, PhD Some patients with heavily treated acute myelogenous leukemia (AML) benefited from treatment with the BCL-2 inhibitor venetoclax (ABT-199), according to a phase II clinical study presented at the 2014 ASH Annual Meeting....

see more →